Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05112536
Title Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors G1 Therapeutics, Inc.
Indications

triple-receptor negative breast cancer

Therapies

Cyclophosphamide + Doxorubicin + Pembrolizumab + Trilaciclib

Carboplatin + Paclitaxel + Trilaciclib

Trilaciclib

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.